Bypassing the Pharma Chokepoint

Introduction Over the last twenty years, China has emerged as the United States and Europe’s [PDF] most important foreign source of upstream inputs of critical medicines—namely, key starting materials (KSMs) and active pharmaceutical ingredients (APIs). As U.S. and EU regulators and media more heavily scrutinized API and KSM production, a process that often involves chemical […]

Source: Council on Foreign Relations